跳至主要内容
临床试验/NCT01050283
NCT01050283终止1 期

A Multicenter Trial to Evaluate 18F-FDG Uptake by PET in Patients With Advanced Pancreatic Adenocarcinoma as an Early Indicator of Drug Activity

Merck Sharp & Dohme LLC0 个研究点目标入组 15 人开始时间: 2010年7月最近更新:
适应症

试验速览

阶段
1 期
状态
终止
入组人数
15
主要终点
Association of changes in FDG uptake with overall survival (OS)

研究概览

简要总结

This study will determine whether [18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET) can be used to screen for the activity of novel pancreatic cancer treatments.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
35 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient has a diagnosis of Stage IV pancreatic adenocarcinoma with distant metastases
  • Patient is scheduled to receive standard chemotherapy containing gemcitabine
  • Patient has not received prior systemic therapy for advanced pancreatic adenocarcinoma
  • Patient must be available for periodic blood sampling, study-related assessments, and management at the treating institution

排除标准

  • Patient has had open abdominal surgery within 6 weeks of the screening visit
  • Patient has had radiotherapy to the thorax, abdomen, or pelvis within 6 months of the screening visit
  • Patient has an active infection, inflammation, or unresolved bowel obstruction
  • Patient has poorly controlled diabetes

结局指标

主要结局

Association of changes in FDG uptake with overall survival (OS)

时间窗: Week 3 and at least 7 months after the last patient is treated

次要结局

  • Association of metabolic response with OS(Baseline, Week 3, and at least 7 months after the last patient is treated)
  • Correlation between FDG standardized uptake values (SUV) at Week 3 and Week 6-7(Week 3 and Week 6-7)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验